The Quantellect read.As of Nov 19, 2026, 8 active firms cover Candel Therapeutics Inc: 8 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $15.00 to $26.00, a moderate spread. The average target of $21.50 sits 304% above the current $5.32. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.34 next quarter toward $-1.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy8100%
Neutral00%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$21.50
+304.1% upside
Average target across 6 active firms as of Nov 19, 2026 vs $5.32 current
Highest Target$26.00
Average Target$21.50
Lowest Target$15.00
Detailed analyst forecasts for CADL
Showing 1–6 of 6 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 8 of 8 active firms rate CADL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CADL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.34
Range $-0.34 – $-0.34 · 1 analysts
Next period, 1 analysts expect Candel Therapeutics Inc to earn $-0.34 a share (range $-0.34 – $-0.34), versus — a year earlier. Full-year consensus is $-1.18, growing to $-1.44 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $9.9M next year.
Top analysts covering Candel Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CADL.
#1
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$23.00+332.3% to target
Overall win rate
45%
+ Follow
#2
SL
Sudan Loganathan
Stephens & Co. · Rank #80
Buy
$15.00+182.0% to target
Overall win rate
47%
+ Follow
#3
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$23.00+332.3% to target
Overall win rate
39%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$26.00+388.7% to target
Overall win rate
38%
+ Follow
#5
SW
Stephen Willey
Stifel · Rank #474
Buy
$22.00+313.5% to target
Overall win rate
29%
+ Follow
CADL stock forecast FAQ
What is CADL's average 12-month price target?+
The 6 active firms with a live target average $21.50 for Candel Therapeutics Inc over the next 12 months, ranging from a $26.00 high to a $15.00 low, as of Nov 19, 2026.
Is CADL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CADL?+
The Street-high target is $26.00 (Citigroup), and the Street-low is $15.00 (Stephens & Co.). The average of all 6 active-firm targets is $21.50.
How many active Wall Street firms cover CADL?+
8 active firms have a recognized rating on Candel Therapeutics Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CADL?+
Among analysts who currently cover CADL, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #73). Their current call is Buy with a $23.00 target.
What is Candel Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.34 per share (range $-0.34 – $-0.34) across 1 analysts. Full-year EPS is projected at $-1.18, rising to $-1.44 the following year.
How much revenue is Candel Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $9.9M next year.
Have analysts been upgrading or downgrading CADL lately?+
As of Nov 19, 2026, 8 of 8 active firms rate CADL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CADL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.